Probi

203SEK +0,5 %
Vær den første som følger denne virksomhed

Probi is a biotechnology company. The company is particularly focused on the research and development of probiotics, a bacterium that is found in the human intestinal system. The research areas within the company include the gastrointestinal, immune system, metabolic syndrome, and stress and recovery. The company's customers include larger corporate customers active in the food industry. The company was founded in 1991 and is headquartered in Lund.

Omsætning
618,29 mio.
EBIT %
8,18 %
P/E
56,86
Udbytteafkast, %
0,64 %
Kursmål
-
Anbefaling
-
Opdateret
-
NASDAQ Stockholm
PROB
Daglig lav / høj pris
193,5 / 203 SEK
Markedsværdi
2,31 mia. SEK
Aktieomsætning
13,22 t SEK
Volumen
66

Major Owners
Source: Millistream Market Data AB

OwnerCapitalVotes
Symrise69,3 %69,3 %
Fjärde AP-fonden9,3 %9,3 %
Premium
Not activated

This content is for our Premium customers only.

Probi CFO to resign

Selskabsmeddelelse05.07.2023
Probi's Annual General Meeting 2023

Selskabsmeddelelse04.05.2023